INTRODUCTION
Mast cells synthesize proteoglycans that are stored in intracellular granules together with histamine and neutral proteinases (Stevens, 1987) . Characterization of mouse and rat mast cells has made it possible to distinguish between two classes of mast cells, referred to as connective-tissue-type and mucosal-type mast cells (for a review on the background for this classification see Stevens, 1986) . Whereas the connective-tissue-type mast cells synthesize predominantly heparin proteoglycans , the mucosal-type mast cells contain mainly chondroitin sulphate proteoglycans (Enerback et al., 1985; Stevens et al., 1986) . Cells belonging to the latter group include bone-marrow-derived mast cells and the rat basophilic leukaemia (RBL-1) cell line (Serafin et al., 1986; Seldin et al., 1985) . The RBL-1 cells have also been shown to synthesize hybrid proteoglycans where heparin and chondroitin sulphate side chains are attached to the same core protein (Seldin et al., 1985) .
The function of the mast-cell proteoglycans may be to serve as a matrix to which histamine and the neutral proteinases are attached by ionic linkage (Schwartz & Austen, 1984) . However, the mast-cell heparin is also a potent anticoagulant, which inhibits several of the bloodcoagulation enzymes by specifically interacting with antithrombin III (Lindahl et al., 1980) . It has been proposed that the mast-cell heparin has a role in the regulation of extravascular coagulation under conditions of inflammation (Lindahl & Pejler, 1987) . The mouse mastocytoma used in the present work has been extensively utilized in studies on the biosynthesis of heparin (see Lindahl et al., 1986; Lindahl & Kjellen, 1987) . The mastocytoma cells resemble the connective-tissue-type mast cells, and synthesize heparin proteoglycans and to a lesser degree also chondroitin sulphate proteoglycans when cultured in vitro (Jacobsson et al., 1985) .
The proteoglycans of both subpopulations of mast cells differ from proteoglycans of most other cell types in their resistance to proteolysis. Amino acid analyses of different mast-cell proteoglycans show that the core proteins, whether substituted with heparin or chondroitin sulphate, have a high content of serine and glycine (Robinson et al., 1978; Metcalfe et al., 1980; Stevens et al., 1985; Seldin et al., 1985) . Robinson et al. (1978) , who studied Pronase-treated rat skin heparin proteoglycans, postulated that the polysaccharide-substituted part of the core protein was composed of alternating serine and glycine residues.
A chondroitin sulphate proteoglycan core protein containing such a Ser-Gly repeat was identified by nucleotide sequence analysis of rat yolk-sac-tumour proteoglycan cDNA clones (Bourdon et al., 1985 (Bourdon et al., , 1986 . The repeat sequence consists of 49 amino acid residues, and the entire core protein contains 179 amino acid residues. Southern-blot analysis has indicated that a single gene in the rat codes for this proteoglycan. The rat mRNA coding for the proteoglycan is expressed only in parietal yolk-sac and in mast cells (Tantravahi et al., 1986; Bourdon et al., 1987b) . On the basis of its high content of alternating serine and glycine residues this gene product has been named serglycin (Ruoslahti, 1988) .
L. Kjelln and others cating that no alternative exon splicing has been used to modify the transcript of the different cell types. However, cell-type-specific differences in the length of the 5' untranslated regions of the mRNAs may be of importance for the regulation of transcription in the different cell types (Bourdon et al., 1987b; Avraham et al., 1988) . A human analogue to rat serglycin, expressed in promyelocytic-leukaemia HL-60 cells, has also been analysed . The predicted amino acid sequence of this protein shows 48 % sequence identity with rat serglycin .
In the present paper we report the complete nucleotide sequence of a serglycin mRNA from the mouse mastocytoma. Immunological data are presented that demonstrate that mouse serglycin is present as a core protein in mastocytoma chondroitin sulphate proteoglycans and heparin proteoglycans.
MATERIALS AND METHODS
Isolation of polyadenylated mRNA RNA was extracted by the guanidinium isothiocyanate method (Chirgwin et al., 1979 ) from a transplantable mastocytoma (Furth et al., 1957) maintained as a solid tumour in (Leaden x A1)Fj mice by intramuscular transplantation in the hind legs every 10-12 days. Healthy mice of the same strain were used as a source of kidney and liver RNA. Rat leukaemic basophils (RBL-1 cell line; Eccleston et al., 1973) grown in spinner cultures were pelleted by centrifugation, frozen in liquid N2 and stored at -70°C before RNA preparation by the same method. Polyadenylated RNA was isolated by chromatography on oligo(dT)-cellulose.
Construction of the bacteriophage A gt 11 cDNA library Double-stranded cDNA was synthesized as described by Huynh et al. (1985) and ligated to EcoRI-digested alkaline-phosphatase-treated bacteriophage A gt 11 DNA, obtained from Promega Biotech, Madison, WI, U:S.A. (Protoclone GT system). Bacteriophage DNA was packaged by use of the same system. The library comprised 0.7 x 105 independent recombinants.
Construction of hybridization probes
Insert DNA of (1) a rat yolk-sac chondroitin sulphate proteoglycan cDNA, pPGl (Bourdon et al., 1985) , (2) the mastocytoma PGM cDNA and restriction fragments from it and (3) a rat IR2 immunocytoma IgE c-chain and K-chain cDNA (Hellman et al., 1982 (Hellman et al., , 1985 were 32p_ labelled by using [ac-32P]dCTP (New England Nuclear) in the RPN.1601Y multiprime DNA labelling system, obtained from Amersham International.
Screening of the bacteriophage library Nitrocellulose replicas of plaques were prehybridized in solution containing 6 x SSC (1 x SSC is 0.15 M-NaC1/0.015 M-sodium citrate buffer pH 7.0), 3 x Denhardt's solution (Denhardt, 1966) , 2 mM-EDTA, 0.5 % SDS and 0.1 mg of yeast RNA/ml for 3 h at 65°C before hybridization for 12-15 h in the same buffer containing 32P-labelled probe. The filters were washed in 2 x SSC/0.5 % SDS. The temperature chosen for hybridization/washing was 42°C and 65°C respectively when pPGl and PGM insert DNA were used as probes.
Subcloning and DNA sequencing cDNA inserts, isolated by agarose-gel or polyacrylamide-gel preparative electrophoresis (Maniatis et al., 1982) after EcoRI restriction of recombinant bacteriophage DNA, were subcloned into pUC19 plasmids. Recombinant plasmids were isolated as previously described (Bywater et al., 1983) . DNA sequencing was performed according to the method of Maxam & Gilbert (1980) .
Primer extension analysis
A DNA fragment of PGM (bp 91-134; see Fig. 1 ), isolated after cleavage of PGM cDNA with BstNI, was 5'-end-32P-labelled with polynucleotide kinase (Biolabs, Beverly, MA, U.S.A.) and mixed with polyadenylated mastocytoma mRNA in 40 mM-Pipes buffer, pH 6.4, containing 1 mM-EDTA, 0.4 M-NaCl and 800% (v/v) formamide. After being heated at 80°C for 10 min, the hybridization mixture was incubated at 60°C for 1 h, at 55°C for 1 h and at 42°C for 2 h before precipitation with ethanol. The extension reaction was catalysed by Moloney-murine-leukaemia-virus reverse transcriptase (Gibco/BRL, Grand Island, NY, U.S.A.) and carried out at 37 'C. After removal of the RNA template by alkaline hydrolysis, the extended material was extracted with phenol, precipitated and dissolved in loading buffer followed by separation on 60 sequencing gels (Maxam & Gilbert, 1980 Southern-blot hybridization Southern-blot hybridization (Southern, 1975 ) was performed as described by Maniatis et al. (1982) . The nitrocellulose filters were washed at 65 'C in 0.1 x SSC/ 0.1 % SDS.
Production of fusion protein and immunization
The insert from the cDNA clone PGM was cloned in the bacterial expression vector pATH 11 (Spindler et al., 1984) , kindly provided by Dr. T. J. Koerner, and transformed into HB101. The resulting fusion protein contains 333 amino acid residues from the trpE protein.
The fusion protein is under control of the trp promoter, which is inducible by 3-(indol-3-yl)acrylic acid. After induction, the bacteria were lysed and the solubilized proteins were separated by SDS/10 %-polyacrylamidegel electrophoresis (Spindler et al., 1984 containing 0.1 0% Triton X-100 and 0.35 M-NaCl. After end-over-end incubation at 4°C overnight, the mixture was poured into a column, which was extensively washed with the equilibration buffer and subsequently with 50 mM-sodium acetate buffer, pH 4.0, containing 0.1 % Triton X-100 and 0.35 M-NaCl. The 35S-labelled proteoglycans were eluted as a single broad peak in a linear gradient of 0.35-1.5 M-NaCl in 50 mM-sodium acetate buffer, pH 4.0, containing 0.1 % Triton X-100. After concentration by ethanol precipitation (Paulsson et al., 1983) , the 35S-labelled proteoglycans were separated from free polysaccharide chains by gel chromatography on a Sephacryl S 400 HR column (Pharmacia) eluted in 50 mM-Tris/HCl buffer, pH 8.0, containing 0.1 % Tn'ton X-100 and 3.0 M-NaCl. The purified proteoglycan fraction contained on an average 100 /,g of hexuronic acid, determined as described by Bitter & Muir (1962) , corresponding to about 0.3 mg of polysaccharide. The heparin content of the 35S-labelled proteoglycans was determined after HNO2 deamination at pH 1.5 (Shively & Conrad, 1976) as previously described (Woods et al., 1984) . Antithrombin-Sepharose (Hook et al., 1976) was kindly given by Dr. Ulf Lindahl, Uppsala, Sweden. The conditions for chromatography on antithrombin-Sepharose were as previously described (Thunberg et al., 1982 (Hunter, 1973) with the use of lodobeads (Pierce Chemical Co.).
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Electrophoresis, immuno-blotting and dot-blotting Electrophoresis was performed on polyacrylamide gradient gels in SDS according to the method of Blobel & Dobberstein (1975) . Immunoblot analysis of proteins electrophoretically transferred to nitrocellulose filters from SDS/polyacrylamide gels was performed as described by Burnette (1981) . For immuno dot-blot analysis, samples were filtered through the membrane by gentle vacuum. Subsequently the nitrocellulose filter was baked for I h at 80 'C. After incubation of the filters with 1/50 dilutions of the appropriate serum, the specifically bound antibodies were allowed to react with 1251_ labelled Protein A. The antigens recognized were detected by autoradiography.
RESULTS cDNA cloning
The cDNA insert from the rat yolk-sac proteoglycan (serglycin) cDNA clone pPGI (Bourdon et al., 1985) the library, and 18 clones were identified. The size of the inserts in these clones varied from 0.5 kb to 0.9 kb. PGM and one of these clones, denoted 4C, were subcloned in pUC19 for further analysis. Nucleotide sequence analysis The complete nucleotide sequence of the insert of clone PGM and partial sequence of the clone 4C were established by the method of Maxam & Gilbert (1980) (see Figs. 1 and 3) . The PGM cDNA is 915 nucleotide residues long and contains the coding region, except for the first two nucleotide residues, and the complete 3' non-coding region along with a short poly(A) tail. The 4C cDNA contains one additional base in the 5'-end, but none of the clones extends to the 5' untranslated region. Primer extension analysis
To obtain the complete mRNA sequence a 44-nucleotide-residue fragment of PGM (bp 91-134) was 5'-end-labelled with polynucleotide kinase and used for primer extension of mastocytoma polyadenylated RNA. The extension products were analysed by electrophoresis on a 60 polyacrylamide gel under denaturing conditions. Only one extension product, containing 135-140 nucleotide residues, was identified (Fig. 2) . This band was excised from the gel, eluted and sequenced. The initiation codon could be identified in addition to a 41-nucleotide-residue 5' non-coding region (see Figs. I  and 3) . Comparison of the structures of the mastocytoma and yolk-sac transcripts and their corresponding proteins
The 938-nucleotide-residue proteoglycan core protein mRNA, poly(A) tail not included, is composed of a 41-residue 5' non-coding region, a 456-residue coding region and a 441-residue 3' non-coding region. A polyadenylation signal (AATAAA) is present 25 residues upstream from the poly(A) site (Fig. 3) . The coding region of the mastocytoma transcript corresponds to a protein with an Mr of 16715. A central region of the protein (amino acid residues 90-109) contains serine and glycine residues in repeating alternating sequence. Nine of the serine residues are contained in the tetrapeptide sequence SerGly-Xaa-Gly, which has been shown to represent the recognition consensus amino acid sequence for the attachment of chondroitin sulphate to protein (Bourdon et al., 1987a) . Comparison of the mastocytoma and yolksac mRNA nucleotide sequences (results not shown), as well as the deduced amino acid sequences of the translated proteins, reveals an extensive sequence similarity (Fig. 3) , identifying the mastocytoma protein as a mouse serglycin. Apart from the potential glycosaminoglycan-attachment region, which in rat serglycin contains 24 Ser-Gly repeats compared with ten in the deduced mastocytoma protein, the two polypeptides show 86 % sequence identify (Fig.   3) . Similarly to the yolk-sac protein (Bourdon et al., 1986) , the mastocytoma serglycin contains a potential signal-peptidase-cleavage site (von Heijne, 1984) , suggesting the presence of a 25-amino acid-residue signal peptide.
Northern-blot analysis
Northern-blot analysis of mouse polyadenylated RNA from different tissue sources, with the PGM clone as a probe, showed that no or very low concentrations of hybridizing mRNA was present in kidney or liver (Fig. 4) . In contrast, polyadenylated RNA isolated from RBL-1 cells contained a hybridizing transcript of size identical with that of the mastocytoma transcript, estimated to 1.1 kb (Fig. 4 ). An estimated transcript size of 1100 residues gives a calculated value of approx. 160 nucleotide residues for the poly(A) tail. Southern-blot analysis Purified fragments originating from different regions of the cDNA clone PGM were used as probes in a Southernblot analysis of mouse genomic DNA (Fig. 5) . Probes corresponding to the C-terminal part of the core protein and the 3' untranslated region of the mRNA (bp 372-958) (see Fig. 3 ) hybridized to one fragment in each restriction digest analysed. A 5' region probe (bp 44-270), devoid of sequence information for the Ser-Gly repeat region (see Fig. 3 for the rat genome (Tantravahi et al., 1986; Bourdon et al., 1987b mastocytoma, this antiserum recognized a single component, with Mr 17000 (Fig. 6) , which probably represents the core protein before glycosylation. When analysed in a dot-blot assay, purified 35S-labelled proteoglycans, containing a mixture of heparin proteoglycans and chondroitin sulphate proteoglycans, were also found to react with the anti-(fusion protein) antibodies (results not shown). However, attempts to precipitate 35S-labelled proteoglycans with the anti-(fusion protein) antibodies were unsuccessful (results not shown), suggesting that immobilization of the proteoglycans on nitrocellulose was essential for immunoreactivity. To determine whether serglycin was present in both heparin proteoglycans and chondroitin sulphate proteoglycans by using the dot-blot assay, it was necessary to obtain a complete separation of the two types of proteoglycans. Since intact proteoglycans could not be separated by either DEAE-Sephacel ion-exchange chromatography or gel chromatography (results not shown), chondroitinase-ABC-generated chondroitin sulphate core proteins and intact heparin proteoglycans respectively were instead purified by a combination of DEAESephacel ion-exchange chromatography and affinity chromatography on antithrombin-Sepharose (Fig. 7) . Proteoglycans isolated from the mastocytoma after labelling with [35S]sulphate in vivo and proteoglycans from the same preparation labelled with 1251 were chromato- graphed in parallel to obtain material for immuno dotblot analysis and to monitor the position of the protein part of the proteoglycans respectively. [The 35S radioactivity does not interfere with the detection of 1251_. labelled Protein A after immuno dot-blotting, as no positive signal was obtained when a non-immune serum was used instead of the anti-(fusion protein) serum (results not shown).] HNO2 treatment of the 35S-labelled proteoglycans followed by gel chromatography on Sephadex G-50 showed that 45 % of the radioactivity was present in heparin (results not shown). After DEAESephacel chromatography of 35S-labelled proteoglycans treated with chondroitinase ABC, approx. 50 % of the 35S radioactivity was retained on the column, whereas the rest of the 35S radioactivity, presumably chondroitin sulphate degradation products, was present in the non-DEAE-Sephacel-binding fractions (Fig. 7b) . When the chondroitinase-ABC-treated 1251-labelled proteoglycans were similarly analysed, the non-DEAE-Sephacel-binding fractions were shown to contain a 1251I-labelled component (Fig. 7b) , whereas the non-digested 12511 labelled material was quantitatively retained by the column (Fig. 7a) . The non-DEAE-Sephacel-binding volume of 600,d respectively were applied to 0.5 ml columns of DEAE-Sephacel before (a) and after (b) chondroitinase ABC digestion. The arrows in (a) and (b) indicate change of buffer: first arrow, 50 mM-Tris/HCI buffer, pH 8.0, containing 0.35 M-NaCl and 0.1 % Triton X-100; second arrow, 50 mM-sodium acetate buffer, pH 4.0, containing 0.35 M-NaCl and 0.1 % Triton X-100; third arrow, 50 mM-sodium acetate buffer, pH 4.0, containing 1.5 M-NaC1 and 0.1 % Triton X-100. Fractions 18-22 in (b) were pooled and dialysed against 50 mMTris/HCl buffer, pH 7.4, containing 0.05 M-NaCl and 0.1 % Triton X-100 before application on 0.6 ml antithrombin-Sepharose columns in a total volume of 1 ml (c). The arrows in (c) indicate change of buffer from 50 mM-Tris/HCI buffer, pH 7A, containing 0.05 M-NaCl (first arrow) to 0.05 M-Tris/HCI buffer, pH 7.4, containing 3 M-NaCl (second arrow). One-tenth of the fractions obtained after chromatography of the 35S-labelled samples were assayed for radioactivity, and 125I radioactivity was measured on the entire fractions. The first fractions contain 600 1 (a and b) and 1000 ,ul (c) and all the following ones 200 4u1. Fractions 3-7 (a), 3-7 (b), 1-5 (c) and 13-17 (c) of the 35S-labelled samples were pooled (total volume 1 ml), and 250 ,ul, 125 ,ul and 62.5 ul fractions thus should contain deglycosylated chondroitin sulphate proteoglycan core proteins. This fraction (derived from the 35S-labelled proteoglycans) gave a positive signal when tested for reactivity with the anti-(fusion protein) antibodies (Fig. 7b) , demonstrating that serglycin functions as a mastocytoma chondroitin sulphate proteoglycan core protein. As expected, no immunoreactive material was present in the corresponding fractions of the untreated 35S-labelled proteoglycans (Fig. 7a) . The DEAE-Sephacel-binding 35S-labelled and "251-labelled macromolecules obtained after chromatography of the chondroitinase-ABC-treated proteoglycans (fractions 18-22 in Fig. 7b ) were applied to Sepharose conjugated with antithrombin. A non-binding and an antithrombin-binding fraction could be recovered (Fig. 7c) . Immuno dot-blot analysis of the 35S-labelled fractions (Fig. 7c) demonstrated that both fractions reacted with the anti-(fusion protein) antibodies. The non-antithrombin-binding macromolecules were not further characterized (however, see the Discussion section), but the identity ofthe antithrombin-binding 125I1 labelled macromolecules as heparin-containing proteoglycans was established by rechromatography of this fraction on antithrombin-Sepharose after heparinase digestion; the enzyme treatment resulted in complete loss of affinity for the gel (results not shown). Furthermore, HNO2 degradation of the antithrombin-binding 35S-labelled macromolecules followed by gel chromatography on Sephadex G-50 showed that the 35S radioactivity was present exclusively in heparin. Hence serglycin apparently occurs also in heparin-containing proteoglycans.
DISCUSSION
Nucleotide sequence data have been used to deduce the complete amino acid sequence of a mouse serglycin. The nucleotide sequence of the mouse transcript and its deduced amino acid sequence are closely related to the cDNA sequence and amino acid sequence of rat serglycin present as a core protein in rat yolk-sac chondroitin sulphate proteoglycans (Bourdon et al., 1985 (Bourdon et al., , 1986 and synthesized by the mucosal-type mast-cell line RBL-1 .
Southern-blot analysis of rat genomic DNA with probes corresponding to either the 3' or the 5' part of serglycin mRNA has indicated that a single gene codes for this protein (Tantravahi et al., 1986; Bourdon et al., 1987b) . Similar results were obtained for the mouse genome when a probe corresponding to the 3' part of mouse serglycin mRNA was used in genomic blot hybridization (Fig. 5 ). However, a 5' probe covering the N-terminal part of the cloned mouse protein identified two hybridizing gene fragments in all four restriction digests (Fig. 5) . Although this resuft could indicate the presence of two serglycin genes in the mouse genome, it is also possible that the serglycin gene contains a large intron with cleavage sites for the restriction enzymes used to generate the genomic mouse fragments. The rat 5' probe, which only identified single gene fragments in the rat genome (Bourdon et al., 1987b) , did not contain sequence information for the signal peptide, which was present in the mouse 5' probe (see Figs. 1 and 3) . If the structures of the rat and mouse genes are similar, this would indicate that the postulated large intron is located between the exon containing sequence information for Vol. 263 (Fig. 5) indicates that the mouse genome, similarly to the rat and human genomes (Tantravahi et al., 1986; Bourdon et al., 1987b; Stevens et al., 1988) , contains multiple genes with sequences similar to this region.
Primer extension analysis demonstrated that the mouse mastocytoma serglycin mRNA, similarly to the rat serglycin mRNA produced by RBL-1 cells (Bourdon et al., 1987b) , contains a short 5' untranslated region. In contrast, mRNA isolated from a rat yolk-sac carcinoma cell line contained an additional 180 nucleotide residues upstream from the 5' cap site of RBL-1 mRNA (Bourdon et al., 1987b) . As discussed by Bourdon et al. (1987b) , the expression of two differently sized serglycin mRNAs could result from the differential use of two promoters, and may suggest that the serglycin gene is controlled by different tissue-specific regulatory sequences.
On the basis of the fact that only gene coding for serglycin was present in the rat genome and that serglycin mRNA was expressed in both mucosal-type and connective-tissue-type must cells, Tantravahi et al. (1986) postulated that serglycin is used as a core protein for both chondroitin sulphate and heparin synthesis. Our results support this notion. On DEAE-Sephacel ionexchange chromatography of a chondroitinase ABC digest of mastocytoma proteoglycans, a non-DEAESephacel-binding fraction that reacted with the anti-(fusion protein) antiserum could be isolated (Fig. 7b) . Since no such material was found on DEAE-Sephacel ion-exchange chromatography of untreated proteoglycans (Fig. 7a) , the chondroitinase-ABC-generated non-DEAE-Sephacel-binding fraction must represent chondroitin sulphate proteoglycan core proteins. However, most of the immunoreactive chrondroitinase-ABCtreated macromolecules were retained on the DEAESephacel column, suggesting that the majority of the chondroitin sulphate proteoglycan core proteins still had the ability to bind to the gel, conceivably via short oligosaccharide stubs generated by the enzyme treatment. The DEAE-Sephacel-binding macromolecules were therefore chromatographed on antithrombin-Sepharose to obtain heparin proteoglycans free from contaminating chondroitin sulphate proteoglycan core proteins (Fig.  7 c) . Chondroitin sulphate does not interact with antithrombin (Teien et al., 1976) , and affinity chromatography on antithrombin-Sepharose can be used to fractionate heparin into a non-binding fraction and two fractions with low affinity and high affinity for antithrombin (Hook et al., 1976) . (The elution conditions used in Fig. 7 will only allow for the separation of heparin with and without affinity for antithrombin respectively.) Immuno dot-blot analysis showed that roughly half of the immunoreactive macromolecules had affinity for antithrombin, thus strongly suggesting that serglycin also occurs in heparin proteoglycans (Fig. 7c) . The non-antithrombin-binding fraction conceivably contains chondroitin sulphate proteoglycan core proteins in addition to heparin proteoglycans lacking affinity for antithrombin. However, it is also possible that a portion of the proteoglycans are hybrids carrying both heparin and chondroitin sulphate side chains on the same core protein. If so, the non-DEAE-Sephacel-binding fraction obtained after chondroitinase ABC digestion would represent core proteins from a population of proteoglycans carrying exclusively chondroitin sulphate chains, whereas the DEAE-Sephacel-binding fraction would contain hybrid proteoglycans and possibly a population of proteoglycans with heparin chains only. In any case, our results demonstrate that serglycin is present in chondroitin sulphate proteoglycans and in heparincontaining proteoglycans. Whether or not the latter are hybrid proteoglycans remains to be determined. However, the fact that no heparin proteoglycan core proteins could be isolated after DEAE-Sephacel ion-exchange chromatography of proteoglycans treated with heparinase (results not shown) may indicate that very few 'pure' heparin proteoglycans are synthesized by the mastocytoma.
As mast cells appear to utilize serglycin for synthesis of both heparin proteoglycans and chondroitin sulphate proteoglycans, regulatory signals other than the primary structure of the newly translated core protein must direct the synthesis of glycosaminoglycans resulting in the production of either type of proteoglycan. Differences in proteolytic cleavage of the newly synthesized mast-cell core protein could conceivably affect subsequent glycosylation. Tentatively, a proteolytic cleavage of the core protein may be a necessary signal for the biosynthesis of one of the polysaccharides but not for the other. Such a signal would allow for the production of hybrid proteoglycans, which then should contain a proteolytically processed core protein. Alternatively, the type of proteoglycan synthesized may depend on the expression of the polysaccharide-synthesizing enzymes. The polysaccharide-protein linkage region, a galactosylgalactosyl-xylosyl trisaccharide sequence, is shared by both kinds of proteoglycans. Polymerization of the polysaccharide chains is achieved by the stepwise transfer of D-glucuronic acid and N-acetyl-D-hexosamine. In heparin biosynthesis the hexosamine transferred is Nacetyl-D-glucosamine, whereas chondroitin sulphate contains N-acetyl-D-galactosamine (for reviews on glycosaminoglycan biosynthesis see Roden, 1980; Lindahl et al., 1986; Lindahl & Kjellen, 1987) . The committing step will be the incorporation of the first hexosamine unit following the linkage region. It is possible that the enzymes responsible for the transfer of these particular hexosamine units are under regulatory control and that the abundancy of these enzymes will determine the relative amounts of heparin proteoglycans and chondroitin sulphate proteoglycans synthesized.
